- Home
- REPL vs HKD Comparison
REPL vs HKD Comparison
Compare REPL & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- HKD
- Stock Information
- Founded
- REPL 2015
- HKD 2003
- Country
- REPL United States
- HKD France
- Employees
- REPL N/A
- HKD N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- HKD Finance: Consumer Services
- Sector
- REPL Health Care
- HKD Finance
- Exchange
- REPL Nasdaq
- HKD Nasdaq
- Market Cap
- REPL 816.4M
- HKD 689.8M
- IPO Year
- REPL 2018
- HKD 2022
- Fundamental
- Price
- REPL $11.05
- HKD $2.99
- Analyst Decision
- REPL Strong Buy
- HKD
- Analyst Count
- REPL 4
- HKD 0
- Target Price
- REPL $17.00
- HKD N/A
- AVG Volume (30 Days)
- REPL 488.6K
- HKD 328.0K
- Earning Date
- REPL 11-12-2024
- HKD 01-01-0001
- Dividend Yield
- REPL N/A
- HKD N/A
- EPS Growth
- REPL N/A
- HKD N/A
- EPS
- REPL N/A
- HKD 0.33
- Revenue
- REPL N/A
- HKD $27,776,448.00
- Revenue This Year
- REPL N/A
- HKD N/A
- Revenue Next Year
- REPL $469.74
- HKD N/A
- P/E Ratio
- REPL N/A
- HKD $8.84
- Revenue Growth
- REPL N/A
- HKD N/A
- 52 Week Low
- REPL $4.92
- HKD $2.61
- 52 Week High
- REPL $12.97
- HKD $6.18
- Technical
- Relative Strength Index (RSI)
- REPL 43.04
- HKD 44.93
- Support Level
- REPL $10.57
- HKD $2.65
- Resistance Level
- REPL $12.73
- HKD $3.06
- Average True Range (ATR)
- REPL 0.67
- HKD 0.18
- MACD
- REPL -0.16
- HKD -0.00
- Stochastic Oscillator
- REPL 20.00
- HKD 52.66
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. The company integrates various digital businesses using its AMTD SpiderNet ecosystem. Its reportable segments are; digital solutions services financial services; digital solutions services non-financial services, hotel operations, hospitality and VIP services, digital media, content and marketing services, and others. The company generates maximum revenue by providing financial digital solutions through its AMTD Risk Solutions, a digital insurance brokerage platform, and PolicyPal which is a digital insurance technology platform. Geographically, the company generates maximum revenue from Hong Kong and the rest from Canada and Singapore.